Skip to site content

National Core Formulary

The IHS National Core Formulary represents the basic standard of care drugs which must be carried by all federal facilities to generally promote the parity, portability, quality, safety, convenience, and cost-effectiveness of the pharmacy benefit.

  • It establishes the "floor" for the pharmacy benefit.
  • Except in closed classes, facilities are expected to add other drugs to the local formulary as needed.
Last Updated: 08/18/2021
Search

Search Medications Results

The following is a list of Medications currently in the queue. 191 record(s) found.
The following is a list of Medications currently in the queue. 191 record(s) found.
MedicationPharmacological CategoryFormulary BriefNotesSimilar Medications
Cyanocobalamin (Vitamin B12), oral Vitamin, Water Soluble Hematologic Supplements (2016)
Folic Acid Vitamin, Water Soluble Supplements in Womens Health (2016) Any product containing >400 mcg / daily dose
Pyridoxine (Vitamin B6) Vitamin, Water Soluble Supplements in Obstetrics (2016)
Vitamin D Vitamin D Analog Vitamin D (2010) *Any product*
Vitamin D Analog (Topical) Vitamin D Analog Psoriasis (2018) *Any product*
Prenatal Multivitamin Vitamin Pregnancy & Prenatal Care (2021) Must contain >400 mcg of folic acid/dose
Vaccines, All ACIP-recommended Vaccines Vaccine (2011) All ACIP recommended vaccines for routine use in accordance with ACIP guidelines
Benzoyl Peroxide AND Clindamycin, topical combination Topical Skin Product, Acne; Topical Skin Product, Acne (Lincosamide Antibiotic) Acne Treatment (2020) Benzoyl Peroxide
Benzoyl Peroxide Topical Skin Product, Acne Acne Treatment (2020) Benzoyl Peroxide AND Clindamycin, topical combination
Tretinoin, topical Topical Skin Product, Acne Acne (2013) *Any product*
Corticosteriods (Topical) - High potency (Class I and II) Topical Corticosteroids Psoriasis (2018) Corticosteroid (Topical) - Intermediate potency; Corticosteroid (Topical) - Low potency
Corticosteroid (Topical) - Intermediate potency Topical Corticosteroids *Any product* Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Low potency
Corticosteroid (Topical) - Low potency Topical Corticosteroids *Any product* Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Intermediate potency
Levothyroxine Thyroid Agent
Laxative, stimulant Stimulant Laxative *Any product*
Nicotine replacement therapy (NRT), combination Smoking Cessation Aid Nicotine Dependence (2015) Combination NRT (nicotine patches + any short-acting NRT product) Bupropion; Varenicline
Moisturizers (both cream- AND petroleum-based) Skin and Mucous Membrane Agent, Miscellaneous; Topical Skin Product Atopic Dermatitis (2020) Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Intermediate potency; Corticosteroid (Topical) - Low potency; Tacrolimus
Salsalate Salicylate
Proton Pump Inhibitor Proton Pump Inhibitor GERD & PUD (2018) *Any product*
Phosphodiesterase 5 (PDE5) Inhibitor Phosphodiesterase-5 Enzyme Inhibitor Phosphodiesterase 5 Inhibitors (2018) *Any product*
Sevelamer carbonate Phosphate Binder Phosphate Binders (2018) For patients on dialysis who cannot use calcium-based phosphate binders due to hypercalcemia Calcium
Varenicline Partial Nicotine Agonist, Smoking Cessation Aid Nicotine Dependence (2015) Bupropion
Ophthalmic Prostaglandin Analog Ophthalmic Prostaglandin Analog Ophth Prostaglandin Analogs (2018) *Any product*
Fluoride, oral Nutritional Supplement Supplements in Oral Health (2016) *Any oral formulation*
Atomoxetine Norepinephrine Reuptake Inhibitor, Selective ADHD (2020) Dextroamphetamine / Amphetamine (immediate release); Dextroamphetamine / Amphetamine (long-acting); Methylphenidate (immediate release); Methylphenidate (long-acting)
Ibuprofen Nonsteroidal Anti-Inflammatory Drug NSAIDs (2014) Diclofenac; Indomethacin; Meloxicam; Naproxen
Indomethacin Nonsteroidal Anti-Inflammatory Drug NSAIDs (2014) Diclofenac; Ibuprofen; Meloxicam; Naproxen
Diclofenac Nonsteroidal Anti-Inflammatory Drug NSAIDs (2014) *Any formulation* Ibuprofen; Indomethacin; Meloxicam; Naproxen
Naproxen Nonsteroidal Anti-Inflammatory Drug NSAIDs (2014) Diclofenac; Ibuprofen; Indomethacin
Meloxicam Nonsteroidal Anti-Inflammatory Drug NSAIDs (2014) Diclofenac; Ibuprofen; Indomethacin; Naproxen
Memantine N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
Low-molecular weight heparin Low-molecular Weight Heparin VTE Prophylaxis (2011) *Any product*
Umeclidinium/vilanterol Long-Acting Muscarinic Antagonist (LAMA) / Long-Acting Beta2 Agonist (LABA) LAMAs (2019) Tiotropium (Spiriva®)
Tiotropium (Spiriva®) Long-Acting Anticholinergic Agent Inhaled Anticholinergics (2011) *Branded product*
Montelukast Leukotriene Receptor Antagonist
Polyethylene glycol Laxative, Osmotic Irritable Bowel Syndrome (2018) *Any product* Lactulose
Iron, oral Iron Salt Hematologic Supplements (2016) *Any oral formulation*
Corticosteroid, intranasal Intranasal Corticosteroid *Any product*
Insulin / Regular human (NovoLIN® R) Insulin, Short-Acting Insulins (2015) *Branded product*
Insulin aspart (NovoLog®) Insulin, Rapid-Acting Insulins (2015) *Branded product*; Pen Device
Insulin detemir (Levemir®) Insulin, Long-Acting Insulins (2015) *Branded product*; Pen Device Insulin glargine (Lantus®)
Insulin NPH (NovoLIN® N) Insulin, Intermediate-Acting Insulins (2015) *Branded product*
Insulin NPH / Regular human insulin (NovoLIN® 70/30) Insulin, Combination (70/30 Mix) Insulins (2015) *Branded product*
Insulin aspart / Insulin aspart protamine (NovoLog® Mix 70/30) Insulin, Combination (70/30 Mix) Insulins (2015) *Branded product*; Pen Device
Ranitidine* Histamine H2 Antagonist GERD & PUD (2018) *(April 1, 2020) The Food and Drug Administration has recommended that all formulations of ranitidine be taken off the market due to contaminates of N-Nitrosodimethylamine (NDMA), a carcinogen, in ranitidine products. Exit Disclaimer: You Are Leaving www.ihs.gov  Proton Pump Inhibitor
H1 Antagonist (2nd generation), long-acting Histamine H1 Antagonist, Second Generation *Any product*
Hydroxyzine Histamine H1 Antagonist, First Generation **COMING SOON**
Estrogen vaginal cream Estrogen Derivative NPTC Meeting Update (May 2018) *Any product* Estradiol tablets
Estradiol tablets Estrogen Derivative Menopausal Hormone Therapy (2016)
Calcium Electrolyte supplement *Any formulation*
Prednisone Corticosteroid, Systemic
Mometasone (Asmanex®) Corticosteroid, Inhalant *Branded product*
Ulipristal Contraceptive; Progestin Receptor Modulator Contraception (2016) Levonorgestrel (Plan B One-Step®)
Medroxyprogesterone, oral Contraceptive; Progestin Polycystic Ovarian Syndrome (2017) Medroxyprogesterone acetate, injection; Oral contraceptive pill, progestin only
Etonogestrel, implant Contraceptive; Progestin Contraception (2016) For use by a skilled and privileged provider Oral contraceptive pill, progestin only
Ethinyl estradiol / Etonogestrel vaginal ring Contraceptive; Estrogen and Progestin Combination Contraception (2016)
Ethinyl estradiol / Norelgestromin, transdermal Contraceptive; Estrogen and Progestin Combination Contraception (2016)
Medroxyprogesterone acetate, injection Contraceptive, Progestin (Injection/Depot) Contraception (2016) Medroxyprogesterone, oral; Oral contraceptive pill, progestin only
Levonorgestrel (Plan B One-Step®) Contraceptive, Progestin Contraception (2016) *Branded product* Ulipristal
Intrauterine device, levonorgestrel Contraceptive, Progestin Contraception (2016) *Any product*; For use by a skilled and privileged provider Intrauterine device, copper
Intrauterine device, copper Contraceptive Contraception (2016) *Any product*; For use by a skilled and privileged provider Intrauterine device, levonorgestrel
Oral contraceptive pill, extended cycle Contraceptive Contraception (2016) *Any product*
Oral contraceptive pill, monophasic: 20mcg EE (low) Contraceptive *Any product* Monophasic: 30-35mcg EE (medium); Oral contraceptive pill
Oral contraceptive pill, monophasic: 30-35mcg EE (medium) Contraceptive *Any product* Monophasic: 20mcg EE (low) ; Oral contraceptive pill
Oral contraceptive pill, progestin only Contraceptive *Any product* Etonogestrel; Implant; Intrauterine Device; Levonorgestrel
Oral contraceptive pill, triphasic Contraceptive *Any product* Monophasics ; Oral Contraceptive Pill
Methylphenidate (immediate release) Central Nervous System Stimulant Pediatric use only Methylphenidate (long-acting)
Methylphenidate (long-acting) Central Nervous System Stimulant Pediatric use only Methylphenidate (immediate release)
Dextroamphetamine / Amphetamine (immediate release) Central Nervous System Stimulant Pediatric use only Dextroamphetamine and amphetamine (long-acting)
Dextroamphetamine / Amphetamine (long-acting) Central Nervous System Stimulant Pediatric use only Dextroamphetamine and amphetamine (immediate release)
Phentermine Central Nervous System Stimulant Obesity Treatment (2018)
Tacrolimus Calcineurin Inhibitor; Immunosuppressant Agent; Topical Skin Product Atopic Dermatitis (2020) Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Intermediate potency; Corticosteroid (Topical) - Low potency; Moisturizers (both cream- AND petroleum-based)
Laxative, bulk-forming Bulk-forming Laxative *Any product*
Alendronate Bisphosphonate Derivative Osteoporosis (2016)
Fluticasone/salmeterol Beta2 Agonist, Long-Acting; Corticosteroid, Inhalant LABAs (2019) Mometasone (Asmanex®)
Albuterol, metered dose inhaler (MDI) Beta2 Agonist NPTC Meeting Update (Nov 2017) *Any product*
Albuterol nebulized solution Beta2 Agonist
Clonazepam Benzodiazepine Alcohol Withdrawal Syndrome (2015) Lorazepam
Lorazepam Benzodiazepine Alcohol Withdrawal Syndrome (2015) Clonazepam
Oseltamivir Antiviral Agent; Neuraminidase Inhibitor Treatment of Influenza (2019)
Pyrazinamide Antitubercular Agent Ethambutol; Isoniazid; Rfapentine ; Rifampin
Rifampin Antitubercular Agent Ethambutol; Isoniazid; Pyrazinamide; Rifapentine
Rifapentine Antitubercular Agent Rifapentine (2013) Ethambutol; Isoniazid; Pyrazinamide; Rifampin
Ethambutol Antitubercular Agent Isoniazid; Pyrazinamide; Rifampin; Rifapentine
Isoniazid Antitubercular Agent Ethambutol; Pyrazinamide; Rifampin; Rifapentine
Methimazole Antithyroid Agent; Thioamide Hyperthyroidism (2021) Propylthiouracil
Propylthiouracil Antithyroid Agent; Thioamide Hyperthyroidism (2021) Methimazole
Oxybutynin, Extended-release Antispasmodic Agent, Urinary Antimuscarinics (2019) Oxybutynin, Immediate-release
Oxybutynin, Immediate-release Antispasmodic Agent, Urinary Antimuscarinics (2019) Oxybutynin, Extended-release
Etanercept -OR- Adalimumab (can choose either product) Antirheumatic, Disease Modifying; Tumor Necrosis Factor (TNF) Blocking Agent TNF Inhibitors (2016) ONLY In consultation with a rheumatologist Adalimumab -OR- Etanercept (can choose either product)
Adalimumab -OR- Etanercept (can choose either product) Antirheumatic, Disease Modifying; Tumor Necrosis Factor (TNF) Blocking Agent TNF Inhibitors (2016) ONLY In consultation with a rheumatologist Etanercept -OR- Adalimumab (can choose either product)
Leflunomide Antirheumatic, Disease Modifying Non-biologic DMARDs (2016) Hydroxychloroquine; Methotrexate; Sulfasalazine
Emtricitabine/tenofovir disoproxil fumarate Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV); Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV) HIV Pre-Exposure Prophylaxis (PrEP) (2018) For (1) Pre-Exposure HIV Prophylaxis, (2) Post-Exposure HIV Prophylaxis (with raltegravir) or (3) HIV Treatment (with raltegravir) in patients with contraindications for 1st line anti-HIV agents Raltegravir
Raltegravir Antiretroviral, Integrase Inhibitor (Anti-HIV) HIV Treatment (2019) For (1) HIV Post-Exposure Prophylaxis (with emtricitabine/ tenofovir DF) or (2) HIV Treatment (with emtricitabine/tenofovir DF) in patients with contraindications for 1st line anti-HIV agents Emtricitabine/tenofovir disoproxil fumarate
Dolutegravir Antiretroviral, Integrase Inhibitor (Anti-HIV) HIV Updates (2020) For HIV treatment in pregnant patients Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
Bictegravir/emtricitabine/tenofovir alafenamide Antiretroviral, Integrase Inhibitor (Anti-HIV) HIV Treatment (2019) Dolutegravir/abacavir/lamivudine; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
Dolutegravir/abacavir/lamivudine Antiretroviral, Integrase Inhibitor (Anti-HIV) HIV Treatment (2019) *Note: HLA B5701 testing required prior to initiation Bictegravir/emtricitabine/tenofovir alafenamide; Dolutegravir; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
Haloperidol decanoate Antipsychotic, Typical (First Generation) - Injectable Long-Acting Injectable Antipsychotics (2020) Injectable Aripiprazole lauroxil
Aripiprazole lauroxil Antipsychotic, Atypical (Second Generation) - Injectable Long-Acting Injectable Antipsychotics (2020) Injectable Haloperidol decanoate
Atypical antipsychotic Antipsychotic, Atypical Atypical Antipsychotic Agents (2015) *Any product* Aripiprazole lauroxil; Haloperidol decanoate
Aspirin Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate
Clopidogrel Antiplatelet Agent Antiplatelets (2015) Aspirin
Carbidopa-Levodopa (immediate release) Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor Parkinson's Disease (2019)
Pramipexole Anti-Parkinson Agent, Dopamine Agonist **COMING SOON**
Methotrexate Antineoplastic Agent; Antirheumatic; Disease Modifying; Immunosuppresant Agent Non-biologic DMARDs (2016) Hydroxychloroquine; Leflunomide; Sulfasalazine
Tamoxifen Antineoplastic Agent, Estrogen Receptor Antagonist; Selective Estrogen Receptor Modulator
Anastrozole Antineoplastic Agent, Aromatase Inhibitor
Letrozole Antineoplastic Agent, Aromatase Inhibitor
Sumatriptan Antimigraine Agent; Serotonin 5-HT 1B/1D Receptor Agonist Triptans (2016) Any two (2) triptan medications are required, one must be sumatriptan
Serotonin 5-HT1 agonist (Triptan) Antimigraine Agent; Serotonin 5-HT 1B/1D Receptor Agonist Triptans (2016) Any two (2) triptan medications are required, one must be sumatriptan Sumatriptan
Lithium Antimanic Agent ER Lithium & Divalproex (2012)
Hydroxychloroquine Antimalarial Non-biologic DMARDs (2016) Leflunomide; Methotrexate; Sulfasalazine
Atorvastatin Antilipemic Agent, HMG-CoA Reductase Inhibitor Dyslipidemia Guideline Review (2014) Pravastatin; Rosuvastatin; Simvastatin
Pravastatin Antilipemic Agent, HMG-CoA Reductase Inhibitor Hyperlipidemia (2017) Atorvastatin; Rosuvastatin; Simvastatin
Simvastatin Antilipemic Agent, HMG-CoA Reductase Inhibitor Dyslipidemia Guideline Review (2014) Atorvastatin; Pravastatin; Rosuvastatin
Rosuvastatin Antilipemic Agent, HMG-CoA Reductase Inhibitor Hyperlipidemia (2017) Atorvastatin; Pravastatin; Simvastatin
Ezetimibe Antilipemic Agent, 2-Azetidinone 2018 ACC/AHA Cholesterol Guidelines (2019)
Chlorthalidone Antihypertensive; Thiazide-Related Diuretic Diuretic Agents (2014) Hydrochlorothiazide
Hydrochlorothiazide Antihypertensive; Thiazide Diuretic Diuretics (2014) Chlorthalidone
Spironolactone Antihypertensive; Mineralocorticoid Receptor Antagonists; Potassium Sparing Diuretic Mineralocorticoid Receptor Antagonist in HF (2017)
Furosemide Antihypertensive; Loop Diuretic Heart Failure Overview (2017)
Diltiazem Antihypertensive; Calcium Channel Blocker, Nondihydropyridine Calcium Channel Blockers (2014) Amlodipine
Amlodipine Antihypertensive; Calcium Channel Blocker, Dihydropyridine Calcium Channel Blockers (2014) Diltiazem
Propranolol Antihypertensive; Beta-Blocker, Non-Selective Beta Blockers (2014) Atenolol; Metoprolol
Metoprolol Antihypertensive; Beta-Blocker, Beta1 Selective Beta-blockers in Heart Failure (2017) Atenolol; Propranolol
Atenolol Antihypertensive; Beta-Blocker, Beta1 Selective Beta Blockers (2014) Metoprolol; Propranolol
Carvedilol Antihypertensive; Beta-Blocker with Alpha-Blocking Activity Beta-blockers in Heart Failure (2017) *Immediate-release only Atenolol; Metoprolol; Propranolol
Lisinopril Antihypertensive, Angiotensin-Converting Enzyme Inhibitor ACEIs & ARBs in Heart Failure (2017)
Losartan Antihypertensive, Angiotensin II Receptor Blocker ACEIs & ARBs in Heart Failure (2017)
Glecaprevir/pibrentasvir (Mavyret®) Antihepaciviral HCV Treatment (2018) Ledipasvir/sofosbuvir (Harvoni®); Sofosbuvir/velpatasvir (Epclusa®)
Ledipasvir/sofosbuvir (Harvoni®) Antihepaciviral HCV Treatment (2018) Glecaprevir/pibrentasvir (Mavyret®); Sofosbuvir/velpatasvir (Epclusa®)
Sofosbuvir/velpatasvir (Epclusa®) Antihepaciviral HCV Treatment (2018) Glecaprevir/pibrentasvir (Mavyret®); Ledipasvir/sofosbuvir (Harvoni®)
Allopurinol Antigout Agent; Xanthine Oxidase Inhibitor Gout (2016)
Ondansetron Antiemetic; Selective 5-HT3 Receptor Antagonist Antiemetic Agents (2021)
Naltrexone, extended-release for injection (**REMS drug**) Antidote; Opioid Antagonist Opioid Use Disorder (2018) **See REMS here** Exit Disclaimer: You Are Leaving www.ihs.gov 
Naloxone Antidote; Opioid Antagonist Treatment of Opioid Overdose (2014)
Naltrexone, oral Antidote; Opioid Antagonist Alcohol Use Disorders (2015) Naloxone
Glucagon Antidote; Hypoglycemia For outpatient use
Glucose, Oral Antidote Glucagon Delivery Devices (2021) Any formulation Glucagon
Loperamide Antidiarrheal Irritable Bowel Syndrome (2018)
Glipizide Antidiabetic Agent; Sulfonylurea Sulfonylureas (2015)
Metformin Antidiabetic Agent; Biguanide
Pioglitazone Antidiabetic Agent, Thiazolidinedione Thiazolidinediones (2017)
Empagliflozin Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor SGLT-2 Inhibitors (2019)
Liraglutide or semaglutide Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist GLP-1 Receptor Agonists (2019) Select either of these subcutaneous agents, no preference given
Semaglutide or liraglutide Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist GLP-1 Receptor Agonists (2019) Select either of these subcutaneous agents, no preference given
Alogliptin Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor DPP-IV Inhibitors (2019)
Nortriptyline Antidepressant, Tricyclic Antidepressants in Pain Mgmt (2014) Amitriptyline
Amitriptyline Antidepressant, Tricyclic Antidepressants in Pain Mgmt (2014) Nortriptyline
Duloxetine Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor/Antagonist Diabetic Neuropathy (2018) Bupropion; Venlafaxine
Venlafaxine Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor/Antagonist SNRIs (2012) Bupropion; Duloxetine
Sertraline Antidepressant, Selective Serotonin Reuptake Inhibitor Citalopram; Escitalopram; Fluoxetine; Paroxetine
Fluoxetine Antidepressant, Selective Serotonin Reuptake Inhibitor Sertraline
Citalopram Antidepressant, Selective Serotonin Reuptake Inhibitor SSRIs (2019) Escitalopram; Fluoxetine; Paroxetine; Sertraline
Escitalopram Antidepressant, Selective Serotonin Reuptake Inhibitor SSRIs (2019) Citalopram; Fluoxetine; Paroxetine; Sertraline
Paroxetine Antidepressant, Selective Serotonin Reuptake Inhibitor SSRIs (2019) Citalopram; Escitalopram; Fluoxetine; Sertraline
Bupropion Antidepressant, Dopamine/Norepinephrine-Reuptake Inhibitor; Smoking Cessation Aid Nicotine Dependence (2015) Varenicline; Venlafaxine
Ethosuximide Anticonvulsant, Succinimide **COMING SOON** Carbamazepine; Clonazepam; Divalproex; Gabapentin; Lamotrigine; Levetiracetam; Phenytoin; Topiramate
Gabapentin Anticonvulsant, Miscellaneous; GABA Analog Gabapentin & Pregabalin in Pain (2014)
Levetiracetam Anticonvulsant, Miscellaneous Antiepileptics (2014) Carbamazepine; Divalproex; Lamotrigine; Phenytoin; Topiramate
Lamotrigine Anticonvulsant, Miscellaneous Antiepileptics (2014) Carbamazepine; Divalproex; Levetiracetam; Phenytoin; Topiramate
Carbamazepine Anticonvulsant, Miscellaneous Antiepileptics (2014) Divalproex; Lamotrigine; Levetiracetam; Phenytoin; Topiramate
Divalproex Anticonvulsant, Miscellaneous ER Lithium & Divalproex (2012) Carbamazepine; Lamotrigine; Levetiracetam; Phenytoin; Topiramate
Topiramate Anticonvulsant, Miscellaneous Antiepileptic Medications (2014) Carbamazepine; Divalproex; Lamotrigine; Levetiracetam; Phenytoin
Oxcarbazepine Anticonvulsant, Miscellaneous **COMING SOON** Carbamazepine; Clonazepam; Divalproex; Gabapentin; Lamotrigine; Levetiracetam; Phenytoin; Topiramate
Phenytoin Anticonvulsant, Hydantoin Antiepileptics (2014) Carbamazepine; Divalproex; Lamotrigine; Levetiracetam; Topiramate
Warfarin Anticoagulant; Vitamin K Antagonist Direct Oral Anticoagulants (2017) Apixaban; Low-molecular weight heparin
Apixaban Anticoagulant; Direct Oral Anticoagulant (DOAC); Factor Xa Inhibitor Direct Oral Anticoagulants (2017) Warfarin
Dicyclomine Anticholinergic Agent Irritable Bowel Syndrome (2018)
Doxycycline Antibiotic, Tetracycline STIs - PART 1 (2021)
Rifaximin Antibiotic, Rifamycin Hepatic Encephalopathy (2020) After failure of, or intolerance to, lactulose monotherapy as indicated for hepatic encephalopathy Lactulose
Penicillin G benzathine Antibiotic, Penicillin STIs - PART 1 (2021)
Azithromycin Antibiotic, Macrolide STIs - PART 1 (2021)
Ceftriaxone Injection Antibiotic, Cephalosporin STIs - PART 1 (2021) Cefixime
Cefixime Antibiotic, Cephalosporin STIs - PART 1 (2021) For outpatient treatment of gonorrhea for Expedited Partner Therapy or when injection therapy is not possible Ceftriaxone Injection
Digoxin Antiarrhythmic Agent, Miscellaneous; Cardiac Glycoside Digoxin Use (2016)
Isosorbide mononitrate Antianginal Agent; Vasodilator Nitroglycerin 0.4 Milligrams; Sublingual; Nitroglycerin patch
Nitroglycerin 0.4 milligrams, sublingual Antianginal Agent; Antidote, Extravasation; Vasodilator Isosorbide mononitrate; Nitroglycerin patch
Nitroglycerin patch Antianginal Agent; Antidote, Extravasation; Vasodilator Isosorbide mononitrate; Nitroglycerin 0.4 milligrams; Sublingual
Buprenorphine, short-acting (**REMS drug**) Analgesic, Opioid; Analgesic, Opioid Partial Agonist **COMING SOON** Any formulation; Restricted to treatment of Opioid Use Disorder; **See REMS here** Exit Disclaimer: You Are Leaving www.ihs.gov  Buprenorphine, long-acting (**REMS drug**); Buprenorphine-naloxone (**REMS drug**)
Buprenorphine, long-acting (**REMS drug**) Analgesic, Opioid; Analgesic, Opioid Partial Agonist **COMING SOON** Any formulation; Restricted to treatment of Opioid Use Disorder; **See REMS here** Exit Disclaimer: You Are Leaving www.ihs.gov  Buprenorphine, short-acting (**REMS drug**); Buprenorphine-naloxone (**REMS drug**)
Buprenorphine-naloxone (**REMS drug**) Analgesic, Opioid; Analgesic, Opioid Partial Agonist Opioid Use Disorder (2018) **See REMS here** Exit Disclaimer: You Are Leaving www.ihs.gov  Naloxone
Acetaminophen Analgesic, Miscellaneous
Lactulose Ammonium Detoxicant; Laxative, Osmotic Cirrhosis & Complications (2015) Polyethylene glycol
Doxazosin Alpha1 Blocker; Antihypertensive Benign Prostatic Hypertrophy (2016) Prazosin; Tamsulosin
Prazosin Alpha1 Blocker; Antihypertensive PTSD Indication (2012) Doxazosin; Tamsulosin
Tamsulosin Alpha1 Blocker Benign Prostatic Hypertrophy (2016) Doxazosin; Prazosin
Epinephrine Injection Devices (both 0.15mg and 0.3mg) Alpha-/Beta- Agonist Epinephrine Injection Devices (2020 Any device, auto-injector or pre-filled syringe
Donepezil Acetylcholinesterase Inhibitor (Central) 5mg and 10mg strengths
Sulfasalazine 5-Aminosalicylic Acid Derivative Hydroxychloroquine; Leflunomide; Methotrexate
Finasteride 5 Alpha-Reductase Inhibitor Benign Prostatic Hypertrophy (2016)